Form4insider filings, from the source

SEC Form 4 · accession 0001104659-15-067092

KYTHERA BIOPHARMACEUTICALS INC · KYTH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Elisabeth Sandoval
Officer — Chief Commercial Officer
Period of report
Sep 22, 2015
Accepted (ET)
Sep 24, 2015 · 9:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001436304

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockSep 22, 2015M10,590$8.22A10,590D
Common StockSep 22, 2015S10,590$74.90D0D
Common StockSep 23, 2015M11,892$8.22A11,892D
Common StockSep 23, 2015S11,892$74.90D0D
Common StockSep 23, 2015M22,690$8.22A22,690D
Common StockSep 23, 2015S22,690$74.90D0D
Common StockSep 23, 2015M26,800$27.50A26,800D
Common StockSep 23, 2015S26,800$74.90D0D
Common StockSep 23, 2015M11,150$44.02A11,150D
Common StockSep 23, 2015S11,150$74.90D0D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock OptionsF1$8.22Sep 22, 2015M10,590D—Apr 2, 2022Common Stock10,59016,749D
Stock OptionsF1$8.22Sep 23, 2015M11,892D—Apr 2, 2022Common Stock11,8924,857D
Stock OptionsF2$8.22Sep 23, 2015M22,690D—Apr 2, 2022Common Stock22,6900D
Stock OptionsF2$27.50Sep 23, 2015M13,400D—Jan 29, 2023Common Stock13,4000D
Stock OptionsF1$27.50Sep 23, 2015M13,400D—Jan 29, 2023Common Stock13,4006,700D
Stock OptionsF1$44.02Sep 23, 2015M11,150D—Jan 22, 2024Common Stock11,15015,608D

Explanation of responses